CCLM:通过自动免疫测试方法筛选结缔组织疾病相关抗体

2018-07-05 MedSci MedSci原创

抗核抗体(ANA)可用于诊断ANA相关的系统性风湿性疾病(AASRD)。本研究的目的是评估免疫测试是否可作为检测17种抗原混合物的抗体间接免疫荧光(IIF)的替代方法。研究人员通过IIF和EliA结缔组织病筛查(Thermo-Fisher)测试了连续测试ANA 9656名患者。对2475名患者进行了医疗记录审查,包括所有通过两种测试呈阳性/疑似患者以及500个阴性对照。结果表明,IIF和EliA之

抗核抗体(ANA)可用于诊断ANA相关的系统性风湿性疾病(AASRD)。本研究的目的是评估免疫测试是否可作为检测17种抗原混合物的抗体间接免疫荧光(IIF)的替代方法。
研究人员通过IIF和EliA结缔组织病筛查(Thermo-Fisher)测试了连续测试ANA 9656名患者。对2475名患者进行了医疗记录审查,包括所有通过两种测试呈阳性/疑似患者以及500个阴性对照。
结果表明,IIF和EliA之间的一致性为83.1%。在12.8%的IIF阳性患者中,30.2%的EliA阳性患者发现AASRD,0.4%,46.6%,5.8%和3.0%的患者分别测试EliA双阴性,双阳性,单阳性IIF为阳性。抗体水平的增加随着AASRD而增加。IIF和EliA分别在系统性红斑狼疮(n = 83)患者为90.4%和69.9%,系统性硬化症患者(n = 63)100%和84.1%,Sjögren综合征(n = 45)患者为86.7%和93.3%,多发性肌炎/皮肌炎(n = 17)患者为88.2%和52.9%,以及在混合结缔组织病的所有病例(n = 8)均为阳性。EliA的特异性预计为94%-96%,IIF的特异性为86%。当所有AASRD结合在一起时,受试者操作曲线的曲线下面积在IIF和EliA之间是相似的。
对AASRD EliA的阳性预测值高于IIF,但是,根据疾病,EliA可能无法检测到IIF检测到的抗体。将免疫分析与IIF相结合可增加其诊断价值。
原始出处:
本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016334, encodeId=fc51201633474, content=<a href='/topic/show?id=932c654e79f' target=_blank style='color:#2F92EE;'>#测试方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65477, encryptionId=932c654e79f, topicName=测试方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Thu May 30 10:53:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662592, encodeId=38d41662592a3, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Thu Dec 27 04:53:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584402, encodeId=ed1a15844021f, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jul 07 04:53:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329526, encodeId=24e732952626, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:35 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016334, encodeId=fc51201633474, content=<a href='/topic/show?id=932c654e79f' target=_blank style='color:#2F92EE;'>#测试方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65477, encryptionId=932c654e79f, topicName=测试方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Thu May 30 10:53:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662592, encodeId=38d41662592a3, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Thu Dec 27 04:53:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584402, encodeId=ed1a15844021f, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jul 07 04:53:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329526, encodeId=24e732952626, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:35 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016334, encodeId=fc51201633474, content=<a href='/topic/show?id=932c654e79f' target=_blank style='color:#2F92EE;'>#测试方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65477, encryptionId=932c654e79f, topicName=测试方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Thu May 30 10:53:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662592, encodeId=38d41662592a3, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Thu Dec 27 04:53:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584402, encodeId=ed1a15844021f, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jul 07 04:53:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329526, encodeId=24e732952626, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:35 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016334, encodeId=fc51201633474, content=<a href='/topic/show?id=932c654e79f' target=_blank style='color:#2F92EE;'>#测试方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65477, encryptionId=932c654e79f, topicName=测试方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Thu May 30 10:53:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662592, encodeId=38d41662592a3, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Thu Dec 27 04:53:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584402, encodeId=ed1a15844021f, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jul 07 04:53:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329526, encodeId=24e732952626, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:35 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2018-07-05 医者仁心5538

    学习了

    0

相关资讯

BMJ:结缔组织疾病相关的间质性肺病的管理

BMJ:结缔组织疾病相关的间质性肺病的管理肺是全身性结缔组织病(CTD)并发症发生的常见部位,CTD累及肺时可出现几种表现。间质性肺疾病(ILD)和肺动脉高血压是最常见的肺部表现。虽然普遍认为ILD的发生晚于CTD,但是ILD通常是CTD最初的表现(以肺部为主要表现的CTD)。大部分CTD可出现ILD,包括类风湿性关节炎、硬皮病、系统性红斑狼疮、多发性肌炎或皮肌炎,舍格伦综合征以及混合性结缔组织病